US2017119733A1PendingUtilityA1

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

35
Assignee: CT INGENIERIA GENETICA BIOTECNOLOGIAPriority: Jul 1, 2011Filed: Nov 10, 2016Published: May 4, 2017
Est. expiryJul 1, 2031(~5 yrs left)· nominal 20-yr term from priority
Inventors:Giselle Penton RolAlexey Llopiz ArzuagaJavier Marin PridaEduardo Penton AriasEfrain Rodriguez JimenezAlexis Musacchio LasaVladimir Armando Besada PérezGilberto Lázaro Pardo AndreuLuis Javier González LópezNancy Pavon FuentesGerardo Enrique Guillen NietoPedro Antonio Lopez Saura
A61P 9/10A61P 25/16A61P 25/28A61P 25/00A61K 38/25C07K 5/081C07K 5/1008A61K 47/55A61K 38/2013C07K 7/06A61K 38/21A61K 38/215C07K 5/08A61K 38/1816A61K 38/212C07K 5/10A61K 38/06A61K 31/409A61K 38/00A61K 38/07A61K 38/08A61K 47/481
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A method for the prophylaxis or the treatment of diseases of the central nervous system (CNS) that progress with ischemic, inflammatory or neurodegenerative damage wherein said method comprises administering a compound selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5 and phycocyanobilin to a subject in need thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.